Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2

NCI-MATCH is a precision medicine trial using genomic testing to allocate patients with advanced malignancies to targeted treatment subprotocols. This report combines two subprotocols evaluating trametinib, a MEK1/2 inhibitor, in patients with Neurofibromatosis 1 (NF1[S1] or GNA11/Q [S2]) altered tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wisinski, Kari B., Flamand, Yael, Wilson, Melissa A., Luke, Jason J., Tawbi, Hussein A., Hong, Fangxin, Mitchell, Edith P., Zwiebel, James A., Chen, Helen, Gray, Robert J., Li, Shuli, McShane, Lisa M., Rubinstein, Lawrence V., Patton, David, Williams, P. Mickey, Hamilton, Stanley R., Behrens, Robert J., Pennington, Kathryn P., Conley, Barbara A., Arteaga, Carlos L., Harris, Lyndsay N., O'Dwyer, Peter J., Chen, Alice P., Flaherty, Keith T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10309549/
https://www.ncbi.nlm.nih.gov/pubmed/37053535
http://dx.doi.org/10.1200/PO.22.00421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10309549/
https://www.ncbi.nlm.nih.gov/pubmed/37053535
http://dx.doi.org/10.1200/PO.22.00421

Ejemplares similares